Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Palliative Care, Emerging Strategies, and Final Thoughts (11 mins)
  • CE

Credits Available
Registered Nurses: 1.0 Nursing contact hour
Released: August 18, 2020 Expiration: August 17, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation
Gayle Jameson, MSN, ACNP-BC, AOCN

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Support patient engagement and decision-making through education and communication
  • Explain to patients the current guidelines and clinical findings on individualized therapies for newly diagnosed advanced pancreatic cancer
  • Evaluate treatment strategies for patients with advanced pancreatic cancer after progression on first-line systemic therapy based on available data and treatment guidelines
  • Discuss the available data and ongoing trials investigating FOLFIRINOX or nab-paclitaxel as neoadjuvant and adjuvant therapy
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage response mutations
  • Manage disease-related and treatment-related symptoms for patients with advanced pancreatic cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Gayle Jameson, MSN, ACNP-BC, AOCN

Associate Investigator, Nurse Practitioner
Oncology Clinical Trials
HonorHealth Research Institute
Scottsdale, Arizona
Adjunct Faculty
Associate Investigator, Nurse Practitioner

Translational Genomics Research Institute
Phoenix, Arizona

Gayle Jameson, MSN, ACNP-BC, AOCN, has disclosed that she has received funds for research support and fees for non-CME/CE services from Celgene.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for oncology nurses and other healthcare providers who care for patients with pancreatic cancer.

Goal

The goal of this activity is to improve nurses’ ability to optimize patient outcomes through live workshops and an online activity that support a shared decision-making approach between clinicians and patients and that accelerate the awareness and integration of evidence-based therapeutic approaches for the treatment of pancreatic cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 18, 2020, through August 17, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Palliative Care, Emerging Strategies, and Final Thoughts (11 mins)
  • CE

In this segment, the expert panelist shares her experiences surrounding symptom management and prevention in palliative care and reviews key emerging strategies in pancreatic cancer treatment, including neoadjuvant and adjuvant therapy.
Gayle Jameson, MSN, ACNP-BC, AOCN
Registered Nurses: 1.0 Nursing contact hour
Released: August 18, 2020 Expiration: August 17, 2021

This program is divided into short segments that you can review from the Activity lnding page.

Related Content

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v1.2020, from CCO

Released: October 16, 2020

Download this slideset from Clinical Care Options, to see the latest data on first-line immunotherapy treatment options for patients with advanced HCC.

Ghassan K. Abou-Alfa, MD, MBA Released: October 14, 2020

Download this slideset from Clinical Care Options, to see the latest data on immunotherapy treatment options for patients with early HCC.

Peter R. Galle, MD, PhD Released: October 14, 2020

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue